Clinical trials: Apatinib
Mucosal Melanoma, Advanced Cancer
Apatinib Plus SHR1210 in Advanced Mucosal Melanoma
There is still no effective treatment for advanced mucosal melanoma at present. The efficacy of single-agent PD-1 inhibitors is less than 20%.
- Conditions
- Mucosal Melanoma, Advanced Cancer, Apatinib, SHR-1210
- Trial name
- NCT03986515
- Testing
- apatinib plus SHR-1210
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Henan Cancer Hospital
NK/T-cell Lymphoma
PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma
This is an open-label, single-center, nonrandomized, Phase 2 study to evaluate efficacy and safety of SHR-1210 combined with Apatinib in subjects with relapsed or refractory NK/T cell lymphoma.Efficacy will be assessed every 8…
- Trial name
- NCT03701022
- Testing
- SHR1210
- Volunteers
- 61 people
- Sponsor
- Peking University
Head and Neck Neoplasms
Apatinib for Advanced Non-squamous Head and Neck Cancer
In this study, the investigators try to evaluate the efficacy and safety of apatinib in advanced non-squamous head and neck cancer and to validate the correlative biomarkers.
- Trial name
- NCT02989259
- Testing
- Apatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
C-staged Hepatocellular Carcinoma in BCLC Classification
A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification
This study was designed to evaluate the effectiveness and safety of hepatic arterial infusion chemotherapy combined with Apatinib and Camrelizumab (treatment group) versus Apatinib and Camrelizumab (control group) for C-staged…
- Trial name
- TRIPLET-III (NCT05313282)
- Testing
- Hepatic Arterial Infusion combined with Apatinib and Camrelizumab, Apatinib combined with Camrelizumab
- Where
- 5 sites in China
- Volunteers
- 140 people
- Sponsor
- Sun Yat-sen University
Gastroesophageal Junction Adenocarcinoma
A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction
The purpose of this study is to assess the efficacy and safety of patients who receive concurrent neoadjuvant chemoradiotherapy for Siewert II ，III of locally advanced HER-2 negative adenocarcinoma at gastroesophageal junction.
- Trial name
- NCT03349866
- Testing
- apatinib, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Hebei Medical University
Nonsmall Cell Lung Cancer
Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC
Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2), shows significant antitumor activity in the patients with GC. The purpose of this study is to determine whether apatinib plus chemotherapy drug can improve…
- Trial name
- NCT03256721
- Testing
- Apatinib/docetaxel/pemetrexed, docetaxel/pemetrexed
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Fuzhou General Hospital
Osteosarcoma, Survival
Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma
Treatment strategies for high-grade osteosarcoma with multidrug chemotherapy and resection result in 3-year event-free survival of 60-70%.
- Conditions
- Osteosarcoma, Survival, Chemotherapy Effect, Toxicity, Drug
- Trial name
- MAPAC (NCT04351308)
- Testing
- MAPI chemotherapy, Apatinib Mesylate, Camrelizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University People's Hospital
Lung Cancer, Non Small Cell Lung Cancer
Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC
The purpose of this study is to evaluate the safety and clinical activity of Apatinib in combination with AP(Pemetrexed/Carboplatin) or AC(Pemetrexed/Carboplatin) as first-line chemotherapy in subjects with advanced EGFR wild…
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer, Combination Chemotherapy, Apatinib
- Trial name
- NCT03201146
- Testing
- Apatinib, AP or AC, Apatinib 250mg
- Where
- China
- Volunteers
- 48 people
- Sponsor
- West China Hospital
Ovarian Cancer Recurrent
The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients
Ovarian cancer is the most lethal gynecological malignancy, posing a serious threat to women's health worldwide.Platinum resistant ovarian cancer is the biggest challenge faced by gynecological oncologists.Exploring more…
- Trial name
- NCT06102707
- Testing
- Fluzopril Combined With Apatinib
- Volunteers
- 50 people
- Sponsor
- Qilu Hospital of Shandong University
Unresectable Hepatocellular Carcinoma
Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
This is a multicenter, randomized, open-label clinical study to evaluate the efficacy and safety of Adebrelimab plus Apatinib (cohort 1), or Adebrelimab plus Bevacizumab (cohort 2), or Camrelizumab plus Apatinib (cohort 3) as…
- Trial name
- NCT06360042
- Testing
- Adebrelimab plus Apatinib, Adebrelimab plus Bevacizumab, Camrelizumab plus Apatinib
- Where
- China
- Volunteers
- 111 people
- Sponsor
- Peking University Cancer Hospital & Institute
Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk
A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma
This study is conducted to evaluate the efficacy and safety of SHR-8068 combined with Adebrelimab and Apatinib compared with Adebrelimab combined with Apatinib in perioperative treatment of resectable hepatocellular carcinoma…
- Trial name
- NCT07682272
- Testing
- SHR-8068 Injection, Adebrelimab Injection, Apatinib Mesylate Tablets
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Ovarian Cancer
Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib
In this study, investigators propose to use fuzuloparib and apatinib as neoadjuvant therapy for Homologous recombination deficiency （HRD）positive advanced ovarian cancer patients, aiming to explore the efficacy and safety of this…
- Trial name
- NCT07033819
- Testing
- Neoadjuvant therapy with fuzuloparib in combination with apatinib, Preoperative Period, Chemotherapy
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hepatocellular Carcinoma Resectable
Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer
This is a single-center, prospective, non-randomized, open-label, phase II clinical trial aiming to evaluate the efficacy and feasibility of using patient-derived tumor organoid drug sensitivity testing (ODST) to guide…
- Trial name
- NCT07363356
- Testing
- Organoid Drug Sensitivity Testing-Guided Therapy
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Esophageal Squamous Cell Carcinoma
SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer
Patients with previously untreated advanced or metastatic esophageal squamous cell carcinoma are recruited to this prospective non-randomized study comprising two separate cohorts.
- Trial name
- NCT03603756
- Testing
- SHR-1210, Apatinib, Irinotecan Injection
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Chinese Academy of Medical Sciences
Non Small Cell Lung Cancer
The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC)
Patients with advanced non-small cell lung cancer (NSCLC) who progress slowly after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors（EGFR-TKI）resistance.
- Trial name
- NCT03811054
- Testing
- Apatinib（250mg/d） combined with EGFR-TKI
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Chest Hospital
Gastric Cancer
Apatinib for the Elderly Advanced Gastric Cancer
The purpose of our study is to assess the efficacy and safety of apatinib in elderly advanced gastric cancer patients, and to find the relationship between the expression of VEGFR-2 and efficacy of apatinib treatment.
- Trial name
- NCT03104283
- Testing
- Apatinib
- Where
- 5 sites in China
- Volunteers
- 48 people
- Sponsor
- Affiliated Hospital of Qinghai University
Gastric Cancer
Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells
The purpose of this study is to assess the efficacy and safety of apatinib as maintenance therapy after adjuvant chemotherapy in progressive gastric cancer patients with positive exfoliative cancer cells.
- Trial name
- NCT02510469
- Testing
- Apatinib
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Hebei Medical University
PD-1 Immunotherapy, VEGFR-TKI
Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma
This study is to explore the treatment of advanced sarcomatoid carcinoma or Carcinosarcoma with Carrelizumab combined with Apatinib, in order to provide guidance and experience for new combined therapy in clinic.
- Conditions
- PD-1 Immunotherapy, VEGFR-TKI, Sarcomatoid Carcinoma, Carcinosarcoma
- Trial name
- NCT05265793
- Testing
- Camrelizumab Combined With Apatinib
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Fudan University
Adenoid Cystic Carcinoma
Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma
It is a randomized phase II study to determine the efficacy and safety of particle therapy with or without apatinib as induction therapy for the treatment of head and neck adenoid cystic carcinoma.
- Trial name
- NCT02942693
- Testing
- Apatinib, Particle Therapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Proton and Heavy Ion Center
Esophageal Squamous Cell Carcinoma
Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment
We conduct the clinical trial to further explore the efficacy and safety of Apatinib combined with chemotherapy in treating recurrent or metastatic esophageal squamous cell carcinoma after the failure of conventional treatments.
- Trial name
- NCT03224221
- Testing
- Apatinib, fluorouracil and platinum
- Where
- China
- Volunteers
- 189 people
- Sponsor
- The First Affiliated Hospital of Anhui Medical University